Travere Therapeutics (NASDAQ:TVTX) Insider Peter Heerma Sells 2,174 Shares

Key Points

• Insider sale: Peter Heerma sold 2,174 shares on May 5 at an average of $46.65 for roughly $101,417 to cover tax withholding on vested equity, reducing his stake by 1.52% to 140,684 shares.
• Q1 results: Travere reported EPS of $0.05 versus a -$0.24 consensus (an EPS beat) and revenue of $127.2M, up 55.6% year‑over‑year but slightly below the $136.2M estimate.
• Analyst outlook: Multiple firms raised targets and ratings (notably TD Cowen to $60 and Wells Fargo to $50), leaving an average analyst target near $47.83 and generally constructive sentiment.

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Peter Heerma sold 2,174 shares of the firm's stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $46.65, for a total value of $101,417.10. Following the transaction, the insider directly owned 140,684 shares in the company, valued at approximately $6,562,908.60. The trade was a 1.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Peter Heerma also recently made the following trade(s):

• On Tuesday, April 14th, Peter Heerma sold 7,215 shares of Travere Therapeutics stock. The stock was sold at an average price of $41.93, for a total value of $302,524.95.

Travere Therapeutics Stock Performance

Shares of TVTX stock traded down $0.10 during mid-day trading on Wednesday, hitting $44.70. 2,390,035 shares of the stock were exchanged, compared to its average volume of 2,890,153. The stock's fifty day simple moving average is $32.59 and its two-hundred day simple moving average is $32.83. The stock has a market capitalization of $4.16 billion, a price-to-earnings ratio of -194.33 and a beta of 1.13. Travere Therapeutics, Inc. has a 12-month low of $13.88 and a 12-month high of $48.61. The company has a debt-to-equity ratio of 3.16, a quick ratio of 2.70 and a current ratio of 3.13.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last announced its earnings results on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.29. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The business had revenue of $127.20 million during the quarter, compared to the consensus estimate of $136.23 million. During the same quarter in the prior year, the firm earned ($0.47) earnings per share. The business's quarterly revenue was up 55.6% compared to the same quarter last year. On average, analysts forecast that Travere Therapeutics, Inc. will post -0.16 EPS for the current year.

Institutional Investors Weigh In On Travere Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Hillsdale Investment Management Inc. lifted its position in Travere Therapeutics by 2.9% in the first quarter. Hillsdale Investment Management Inc. now owns 182,320 shares of the company's stock valued at $5,417,000 after purchasing an additional 5,100 shares during the period. Fifth Third Bancorp acquired a new stake in shares of Travere Therapeutics during the 1st quarter valued at approximately $35,000. Hsbc Holdings PLC acquired a new stake in shares of Travere Therapeutics during the 1st quarter valued at approximately $11,788,000. Burney Co. acquired a new stake in shares of Travere Therapeutics during the 1st quarter valued at approximately $1,180,000. Finally, Stephens Investment Management Group LLC lifted its position in shares of Travere Therapeutics by 4.5% during the 1st quarter. Stephens Investment Management Group LLC now owns 1,798,466 shares of the company's stock valued at $53,432,000 after acquiring an additional 76,843 shares during the period.

Key Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target from $45 to $60 and kept a "buy" rating, implying meaningful upside vs. current levels — a bullish signal from a major sell‑side shop. TD Cowen price target raise
• Positive Sentiment: Wells Fargo upgraded its target to $50 and assigned an "overweight" rating, another near‑term positive catalyst supporting higher valuation expectations. Wells Fargo price target raise
• Neutral Sentiment: HC Wainwright reiterated a "Buy" and $57 target but trimmed FY2027–FY2030 EPS forecasts slightly (e.g., FY2027 cut from $0.71 to $0.60; FY2030 to $4.59 from $4.61). The firm still models substantial multi‑year growth, so this is more of a modest forecast tweak than a change in conviction. HC Wainwright note
• Neutral Sentiment: Earnings call transcript for Q1 2026 is available — recall Travere reported a year‑over‑year revenue gain and an EPS beat in the quarter, which helped underpin recent analyst upgrades. Review the transcript for management commentary on sparsentan commercialization and margin trajectory. Q1 2026 earnings transcript
• Negative Sentiment: Director Roy Baynes sold 9,750 shares (about $431k at the sale price) under a pre‑arranged Rule 10b5‑1 plan. Insider sales can be perceived negatively by the market despite the trading plan disclosure; monitor for any further insider activity. Insider sale filing

Analyst Ratings Changes

TVTX has been the topic of a number of research reports. Weiss Ratings reissued a "sell (e+)" rating on shares of Travere Therapeutics in a report on Wednesday, January 21st. Wells Fargo & Company raised their price target on Travere Therapeutics from $40.00 to $50.00 and gave the stock an "overweight" rating in a report on Wednesday. Citigroup raised their price target on Travere Therapeutics from $53.00 to $59.00 and gave the stock a "buy" rating in a report on Tuesday. Piper Sandler raised Travere Therapeutics from a "neutral" rating to an "overweight" rating and set a $49.00 price target on the stock in a report on Tuesday, April 14th. Finally, Wall Street Zen lowered Travere Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Saturday, February 21st. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Travere Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $47.83.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.